Scynexis has nabbed Nkechi Azie as its VP of clinical development from her role as infectious disease head at The Medicines Company.
UniQure is reportedly working with advisers to assess options including a sale or partnership but is yet to decide on which path to take.
Outgoing BIO Chair John Maraganore and his successor, Jeremy Levin, reflected on drug pricing, its drivers and its place in the innovation ecosystem.
The study is assessing the effect of the oral AXL inhibitor when given to elderly AML patients in combination with low-intensity chemotherapy.
Novartis welcomes new pharma chief Tschudin after Hudson jumps to Sanofi; F-star nabs immuno-oncology exec from BMS; and Grail finds a new CEO.
The proportion of patients who had a greater than 1 g/dL increase in hemoglobin is down on GBT’s prior update but still superior to placebo.
Manipulating brain signals called sharp wave ripples may guide the design of future treatments for memory disorders.
GlaxoSmithKline is joining forces with the University of California to dig into how gene mutations cause disease and use CRISPR to discover new drugs.
A Columbia University team has developed a CRISPR alternative that uses a bacterial “jumping gene” to insert DNA sequences.
In this week's EuroBiotech Report, J&J bags option on Darzalex successor, Sobi overhauls R&D group and ReViral hires CEO.